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Abstract
Pediatric uveitis is a topic of special interest not only because of the unique diagnostic and therapeutic
challenges but also because of the lifetime burden of vision loss if the problem is not adequately
treated, as well as the economic and psychological toll on the family. Often, uveitis in children is
discovered as part of a routine eye exam; this silent, insidious inflammation can be difficult to treat
and can lead to further complications if not handled skillfully. Corticosteroids have long been the
mainstay of therapy; however, the significant associated side effects mandate a corticosteroid-sparing
therapeutic regimen in pursuit of remission. In this review, we cover the therapeutic options for
pediatric uveitis, specifically focusing on the most common non-infectious varieties, juvenile idiopathic
arthritis-associated uveitis and pars planitis.
Introduction
While the incidence and prevalence of uveitis in children is
less than that of adults [1,2], pediatric uveitis deserves
special attention because of its unique diagnostic and
therapeutic challenges, the lifetime burden of blindness if
the problem is not cured, and the economic and
psychologicaltollonthefamily.Childrenmakeupbetween
2.2% and 13.8% of patients in uveitis clinics [1-3]. Uveitis
inchildrenisoftendiscoveredaspartofaroutineeyeexam,
as many children do not report any symptoms, and is more
likely to be chronic, recurrent, and difficult to treat.
Providers may also face difficulty in getting a complete
historyandreviewofsystemsinuncooperativeorpreverbal
children; general anesthesia is sometimes necessary for a
complete exam in very young children.
The risk of poor visual outcomes in children may be
greater than in the adult population, due to a delay in
diagnosis and established ocular pathology. Between
suboptimal therapy and tolerance to insidious inflam-
mation, children are prone to complications and may
silently develop cataract, glaucoma, band keratopathy, or
amblyopia. Furthermore, the presence of complications
or established pathology at presentation is a significant
risk factor for further complications [4,5].
Treatment options are many, and providers must be
conscious of the potentially vision-threatening prognosis
of uveitis in a child who is not treated quickly and
appropriately. In the cases that are not resolved by initial
corticosteroid therapy, providers must be keen to initiate
immunomodulatory therapy early on. Extensive use of
corticosteroidsin childrencanhave significantsideeffects;
the child with recalcitrant uveitis should be co-managed
with a rheumatologist or referred immediately to an
ophthalmologist with the ability to adequately establish
andmonitorimmunosuppressivetherapies,suchasclassic
immunomodulators or biologic response modifiers.
Differential diagnosis
Uveitis in children can generally be identified as having
one of three following causes: infectious; non-infectious
(e.g. as part of an underlying autoimmune syndrome); or
as a manifestation of a masquerade syndrome. The
clinical investigation should be initiated and conducted
based on a detailed family and past medical history, the
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granulomatous or non-granulomatous inflammation
(Table 2) [6]. The variety of manifestations in numerous
uveitic entities is broad and includes many of the same
entities seen in adults. Infectious and non-infectious
entities of special importance to the pediatric age group
aresummarizedinthisarticlebythemostcommoncauses.
Infectious vs. non-infectious uveitis
There is an estimated incidence of 4.9–6.9 per 100,000
person-years, and prevalence of 13–30 per 100,000
population, of non-infectious anterior uveitis in the
North American population [7]. Juvenile idiopathic
arthritis is the most common systemic association of
pediatric uveitis [7].
Treatment for non-infectious pediatric uveitis is multi-
factorial. Topical and oral corticosteroids are used to treat
acute inflammation. Corticosteroid-sparing agents should
be introduced to control the inflammation. Immunomo-
dulatory therapy has been associated with positive
outcomes in non-infectious pediatric uveitis, but therapy
can be limited by medication-related side effects [8].
Infectious diseases such as toxoplasmosis, toxocariasis,
Lyme disease, syphilis, tuberculosis, and some viruses
can be common causes of pediatric uveitis, especially in
developing countries [9]. These infectious diseases can be
successfully treated with specific antimicrobial interven-
tions, and thus careful and extensive systemic work up of
these causes must be performed to rule out infections
prior to the institution of treatment [10].
Juvenile idiopathic arthritis
Juvenile idiopathic arthritis is a systemic autoimmune
diseaseandcanbedefinedasagroupofidiopathicarthritis
diseases that occurs before the age of 16 and persists for at
least 6 weeks. The peak age of onset is between the ages of
6 months and 4 years. Juvenile idiopathic arthritis affects
approximately 70,000 children in the US. Its pathogenesis
appears to be multifactorial; genetic predisposition has
been implicated, and the onset is possibly triggered by
microbial contact [6]. The most common extra-articular
manifestation of juvenile idiopathic arthritis is intraocular
inflammation. The prevalence of uveitis in juvenile
idiopathic arthritis patients can range from 4% to 38%
andvariesbyjuvenileidiopathicarthritissubtype,themost
common being oligoarticular onset [11,12]. Juvenile
idiopathic arthritis patients with uveitis typically present
with bilateral non-granulomatous uveitis. However, gran-
ulomatous uveitis with mutton-fat keratic precipitates can
occur[13]. Rarely, theposteriorsegment of the eye canalso
be involved.
The leading cause of visual impairment in juvenile
idiopathic arthritis is complicated cataract and band
keratopathy. Othercomplications associatedare secondary
glaucoma, epiretinal membrane formation, macular hole,
hypotony with ciliary body shutdown or atrophy. The
diagnosis should include a careful review of the symptoms
and general examination of patients, often with rheuma-
tologist co-management. Early diagnosis and prompt
treatment to achieve complete resolution of inflammation
is the goal for the prevention of sight-threatening
complications in juvenile idiopathic arthritis [6,14,15].
Pars planitis
The term “intermediate uveitis” should be used for that
subset ofuveitiswhere the vitreousisthe majorsiteof the
inflammation. It is estimated that intermediate uveitis
represents one-fifth of all cases of pediatric uveitis [6].
According to Standardization of Uveitis Nomenclature
(SUN) criteria, the term “pars planitis” should be used
onlywhenthereisintermediateuveitiswithsnowbankor
snowball formation, in the absence of an associated
infection or systemic disease [16]. Identification of
vitreous cells at slit lamp examination is the sine qua
non of this disease. Usually, patients with pars planitis
present with complaints of blurry vision and floaters.
Symptoms such as redness, painful eyes and tearing are
less common. Children can be diagnosed with inter-
mediate uveitis incidentally on routine ophthalmic
examination because significant anterior segment
inflammation is not very frequent. Children with pars
planitis have worse visual acuity,both at diagnosis and at
follow-up, than adults. Complications such as cataract,
cystoid macular edema, secondary glaucoma, vitreous
hemorrhage and retinal detachment can occur [4,17].
Treatment
The stepladder approach
The preferred treatment strategy for non-infectious uveitis
is the so-called “stepladder approach”. With anterior
inflammation, aggressive topical corticosteroids are
initiated as the first-line treatment; if this does not quiet
the inflammation, local corticosteroid injections are
added to the regimen. Careful monitoring of intraocular
pressure during a topical steroid regimen is important.
Systemic steroid treatment can also be implemented, but
in brief courses (less than three months), as there can be
serious long-term side effects, including growth retarda-
tion due to adrenal suppression and premature closure of
the epiphyseal plates [18]. Weight gain, hyperglycemia,
infection, or osteoporosis can also occur due to extensive
use of corticosteroid [18]. As topical steroids are generally
ineffective at penetrating the eyeball to the posterior
segment, systemic treatment or regional injections may be
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Anterior non-granulomatous Anterior granulomatous
￿ Juvenile idiopathic arthritis
￿ Herpetic disease
￿ HLA-B27-associated disease
￿ Systemic lupus erythematosus
￿ Fuchs’ heterochromic iridocyclitis
￿ Kawasaki disease
￿ Tubulointerstitial nephritis and uveitis
￿ Trauma
￿ Viral syndromes
￿ Post bacterial infection (Yersinia, Streptococcal)
￿ Amantiades-Behçet’s disease
￿ Human immunodeficiency virus
￿ Leukemia
￿ Drug induced
￿ CINCA/NOMID
￿ Juvenile xanthogranuloma
￿ Sarcoidosis
￿ Herpetic disease
￿ Inflammatory bowel disease
￿ Syphilis
￿ Lyme disease
￿ Leprosy
￿ Tuberculosis
￿ Trauma
￿ Sympathetic ophthalmia
￿ Fungal disease
￿ Multiple sclerosis
Intermediate uveitis Panuveitis
￿ Pars planitis
￿ Juvenile idiopathic arthritis
￿ Multiple sclerosis
￿ Lyme disease
￿ Cat-scratch disease
￿ Toxocariasis
￿ Masquerades
￿ Sarcoidosis
￿ Tubulointerstitial nephritis and uveitis
￿ Syphilis
￿ Familial juvenile systemic granulomatosis
(Blau syndrome)
￿ Amantiades-Behçet’s disease
￿ Sympathetic ophthalmia
￿ Orbital pseudotumor
￿ Vogt–Koyanagi–Harada syndrome
￿ Lyme disease
￿ Cat-scratch disease
￿ Masquerades
￿ Sarcoidosis
￿ Tubulointerstitial nephritis and uveitis
Posterior uveitis without vasculitis Posterior uveitis with vasculitis
￿ Toxocariasis
￿ Leukemia
￿ Tuberculosis
￿ Vogt–Koyanagi–Harada syndrome
￿ Trauma (intraocular foreign body)
￿ Rubella
￿ Diffuse subacute unilateral neuroretinitis
￿ Endophthalmitis
￿ Presumed ocular histoplasmosis syndrome
￿ Masquerades
￿ White dot syndromes
￿ Toxoplasmosis
￿ Sarcoidosis
￿ Syphilis
￿ Lyme disease
￿ Acute retinal necrosis (HSV/VZV)
￿ Cytomegalovirus retinitis
￿ Human immunodeficiency virus
￿ Multiple sclerosis
￿ Paraviral syndrome
￿ Masquerades
￿ Kawasaki disease
￿ Amantiades-Behçet’s disease
￿ Polyarteritis nodosa
￿ Granulomatosis with polyangiitis (Wegener’s)
￿ Systemic lupus erythematosus
￿ Inflammatory bowel disease
HLA, human leukocyte antigen; HSV, herpes simplex viruses; NOMID, Neonatal-onset multisystem inflammatory
disease; CINCA, Chronic infantile neurological, cutaneous and articular syndrome; VZV, Varicella zoster virus.
Adapted with permission from Diagnosis and Treatment of Uveitis, Chapter 81 [6].
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When tapering the corticosteroids leads to a recurrence of
inflammation, the second step in the ladder involves
systemic non-steroidal anti-inflammatory medications
(NSAIDs). Naproxen and tolmentin have the longest
history of successful use among pediatric rheumatologists
[19].Celecoxibanddiflunisal,inourexperience,provedto
be useful in controlling human leukocyte antigen (HLA)-
B27-associated anterior uveitis such as that seen in
ankylosing spondylitis and the other spondyloarthropa-
thies [20]. However, should these therapies prove to be
insufficient, early initiation of immunomodulatory ther-
apy is key. Methotrexate is generally the first choice, as it
has a well-established safety and efficacy profile in
children and does not appear to increase the risk of cancer
[21]. Wetypicallybegintreatment ofa childat0.15mg/kg
orallyonceaweek,andincreasethedosageevery6-8weeks
until stable quiescence, entirely without corticosteroids, is
observed. In juvenile idiopathic arthritis-associated uveitis,
the dose required to keep uveitis in remission is typically
higher than that required to relieve joint symptoms, but
children generally tolerate higher doses well [19]. Addi-
tionally, dosage of methotrexate is based on weight, so
dose adjustments must be made carefully as the child
grows. If uveitis persists after several dose increases, it is
advisable to switch to the subcutaneous dosage form, as
thebioavailabilityafteroraladministrationcanbevariable.
If the dose exceeds 17.5 mg, we typically switch to the
subcutaneous form. Significant potential side effects of
methotrexate include bone marrow suppression, hepato-
toxicity, and interstitial pneumonitis, which is why it is
crucial that a provider must be an expert in the prescribing
and monitoring of methotrexate therapy, or work with a
rheumatologist. As methotrexate is a folic acid analogue,
addingaregimenof1mgoffolicacideverydayoftheweek
except the day that the medication is taken, or 5 mg of
leukovorin once a week, reduces the risk of side effects.
Approximately three-quarters of juvenile idiopathic arthri-
tis patients experience improvement in inflammation with
methotrexate as monotherapy [21]. In those that do not
improve, the other classic immunomodulators should be
explored: azathioprine, mycophenolate mofetil, or cyclos-
porine can be substituted. Azathioprine is moderately
e f f e c t i v ei nb o t hc h i l d r e na n da d u l t s[ 2 2 ] ,b u ti sl e s s
commonly prescribed in children, as gastrointestinal side
effectsaremorecommon thaninthe other antimetabolites
[23]. Mycophenolate mofetil may be effective in quieting
inflammation in over half of those cases refractory to
methotrexate [24] and, in non-juvenile idiopathic arthritis
uveitis,issometimesusedinsteadofmethotrexateasafirst-
line corticosteroid-sparing agent [8].
Cyclosporine A (CsA), a calcineurin inhibitor that prevents
T-cell activation, can be used on its own or in conjunction
with the former two antimetabolites. Cyclosporine has
been observed to be particularly effective in patients with
Behçet’s disease-associated uveitis [25]; in children with
juvenile idiopathic arthritis-associated uveitis, cyclosporine
is more effective when used in combination with
methotrexate [26]. Initial dosing is recommended at 3-5 mg/
kg/day divided into two doses, followed by a main-
tenance dose of 2-3 mg/kg/day [6,27]. Less widely used
T-cell inhibitors include tacrolimus and sirolimus and,
although current data in children are lacking, with more
research they may become options in the future. Some
individuals may experience hypertension as a side effect of
both cyclosporine and tacrolimus, so monitoring of blood
pressure is warranted. Additionally, these drugs may have
Table 2. Differential diagnosis of intermediate and posterior
pediatric uveitis: age at presentation
Infants (age 0-2 years) Children (age 2-10 years)
￿ Toxoplasmosis
￿ Lymphocytic choriomeningitis
virus
￿ HSV retinitis
￿ Retinoblastoma
￿ Rubella
￿ Congenital syphilis
￿ Toxoplasmosis
￿ Toxocariasis
￿ Leukemia
￿ Juvenile idiopathic arthritis
￿ Cat-scratch disease
￿ Subacute sclerosing panencephalitis
￿ CINCA/NOMID syndrome
￿ Familial juvenile systemic
granulomatosis (Blau syndrome)
Adolescents (10-20 years) Any childhood age
￿ Juvenile idiopathic arthritis
￿ Pars planitis
￿ HLA-B27 associated disease
￿ Toxoplasmosis
￿ Acute posterior multifocal placoid
pigment epitheliopathy
￿ Presumed ocular histoplasmosis
syndrome
￿ Diffuse subacute unilateral
neuroretinitis
￿ Leukemia
￿ HIV retinopathy
￿ CMV retinitis
￿ Acute retinal necrosis
￿ Endophthalmitis
￿ Sarcoidosis
￿ Lyme disease
￿ Cat-scratch disease
￿ Tubulointerstitial nephritis and
uveitis syndrome
￿ Tuberculosis
￿ Vogt-Koyanagi-Harada syndrome
￿ Sympathetic ophthalmia
￿ Amantiades-Behçet’s disease
￿ Traumatic (intraocular foreign
body)
HLA, human leukocyte antigen; NOMID, Neonatal-onset multisystem
inflammatory disease; CINCA, Chronic infantile neurological, cutaneous
and articular syndrome. Adapted with permission from Diagnosis and
Treatment of Uveitis, Chapter 81 [6].
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Biologic response modifiers
The most recent additions to the treatment options of
both children and adults with uveitis are the biologic
therapies, which are typically monoclonal antibodies
designed to halt the inflammatory cascade by binding
and inhibiting proinflammatory cytokines.
The tumor necrosis factor (TNF)-alpha inhibitors inflix-
imab and adalimumab are shown to be the most
effective in their class at controlling ocular inflamma-
tion, and can be used on their own or in combination
with classic immunomodulatory therapy, when one or
the other is insufficient [28-31]. An expert panel of the
American Uveitis Society released its recommendations
on the use of infliximab and adalimumab as first-line
agents in the treatment of Behçet’s, as second-line in the
treatment of juvenile idiopathic arthritis-associated
uveitis after methotrexate, and as potential second-line
agents for posterior or panuveitis, or in patients who
have failed to respond to the classic immunomodulators
[32]. Infliximab, a mouse/human chimeric antibody, is
given by intravenous infusion at doses of 5-20 mg/kg
every 4 weeks, after an induction period [28]. Low dose
antimetabolite therapy is usually given in conjunction
with infliximab to prevent antichimeric antibodies [33].
Adalimumab, a fully humanized monoclonal antibody,
may be given at a dose of 20-40 mg every 7 to 14 days
and is administered by subcutaneous injection. While
infliximab has a faster onset, adalimumab has less risk of
infection and greater ease of administration by sub-
cutaneous injection. Some data suggest that adalimumab
may be slightly more effective than infliximab in
achieving remission [29,34], while other studies indicate
no difference between the two. Trials are currently
underway to evaluate the effectiveness of methotrexate
and adalimumab combined therapy versus adalimumab
monotherapy [35].
Golimumabandcertolizumabpegolaretwootherdrugsin
this class that have been used to treat other autoimmune
diseases such as rheumatoid arthritis. As for their effective-
ness in uveitis, data are limited to case reports [36,37].
Etanercept, although effective in treating the systemic
rheumatological manifestations of juvenile idiopathic
arthritis, should not be used in preference to the other
TNF-alpha inhibitors, as it is less effective in controlling
ocular inflammation [32].
Biologics that target other immune cells may aid in the
cases of uveitis that are refractory to anti-TNF therapies
but the current data, especially in children, are limited.
Tocilizumab, an inhibitor of the proinflammatory cyto-
kine interleukin (IL)-6, has been noted in several case
reports to be potentially effective in the treatment of
uveitis that does not respond to anti-TNF agents [38,39].
Rituximab, an anti-CD20 monoclonal antibody approved
for treatment of rheumatoid arthritis, lymphomas, and
leukemias, was shown to control uveitis in 7 out of 10
patients with juvenile idiopathic arthritis uncontrolled by
anti-TNF or immunomodulatory agents [40]. Casereports
also show that abatacept, a cytotoxic T-lymphocyte
antigen (CTLA)-4 fusion protein that inhibits T-cell
co-stimulation, is another agent that has been successful
in controlling inflammation in refractory juvenile idio-
pathic arthritis-associated uveitis [41,42]. Many clinical
trials are underway to assess potential biologic therapies,
including sarilumab (anti-IL6), anakinra (anti-IL1), uste-
kinumab(anti-IL23,anti-IL12),canakinumab(anti-IL-1b),
and gevokizumab (anti-IL-1b).
Intravenous immunoglobulin represents another option
for uveitis refractory to other therapies; it is unique in
that it treats autoimmune disease without suppressing the
immune system. Intravenous immunoglobulin is cur-
rently used in rheumatology and ophthalmology for
vasculitis, systemic lupus erythematosus (SLE), mucous
membranepemphigoid and uveitis,and iscurrently being
studied in a wide range of other conditions [43]. Case
reports show intravenous immunoglobulin as effective in
treating uveitis refractory to other treatments, although
more data are necessary [44,45]. Doses for immunomo-
dulation are given at 2 grams/kg by intravenous infusion
over a course of 2-3 days in 1 week, once monthly.
Other treatments
The cytotoxic alkylating agents chlorambucil and cyclo-
phosphamide are almost always effective in reducing
inflammation, but are used only as a last-resort due to
potential serious long-term side effects [46,47]. Prolonged
use increases theriskofdeveloping amalignancy.Thisrisk
can be mitigated by limiting the total cumulative dose
and duration to one year or less. Alkylating agents are
sometimes associated with significant gonadal dysfunc-
tion or infertility in post-pubescent patients, and the
effects may or may not be reversible. In girls, ovarian
suppression can be induced to protect ova during the
course of treatment [48].
Procedural interventions, such as pars plana vitrectomy,
are preferred to systemic treatments in certain cases of
recurrent pars planitis in order to mechanically clear out
inflammatory cells. In our retrospective medical record
review of 20 pediatric patients (28 eyes) who underwent
pars plana vitrectomy, quiescence of uveitis was achieved
at last follow-up, with or without adjuvant therapy, in
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was 13.5 months [49]. Providers should discuss both
surgical interventions and long-term immunomodulatory
therapy with the family to decide on the most appropriate
option.
Implantable corticosteroid-eluting intravitreal devices,
such as the fluocinolone acetonide implant (Retisert
©) or
the dexamethasone implant (Ozurdex
©), represent surgical
options for the recalcitrant case. However, the data in
children are quite lacking. Retisert
© releases 0.59 mg of
fluocinolone acetonide over 30 months [50] and Ozurdex
©
releases 0.7 mg of dexamethasone over 6 months [51].
Some case reports have indicated successful treatment of
intermediate uveitis or panuveitis with the dexamethasone
implant with minimal side effects at 3 [52] or 6 [53]
months. However, with both devices, there remains a
substantial risk of developing cataract and glaucoma,
though the risk may be higher with the fluocinolone
acetonide implant [54]. In the interest of avoiding future
cataract surgery and other complications, these devices are
used infrequently in children.
Conclusion
The goal with any patient is ultimately steroid-free
durable remission, in total quiescence for a minimum of
two years before tapering therapies. Pediatric uveitis
represents a unique challenge in both diagnosis and
therapy, but it is essential that appropriate treatment be
instated promptly. An ophthalmologist should still
monitor children with juvenile idiopathic arthritis but
without ocular symptoms so that treatment may be
instated rapidly in the event that uveitis develops. The
stepladder approach is the preferable method, beginning
with corticosteroid therapy to quickly abolish inflamma-
tion, and then advancing to classic immunomodulators,
adding biological therapies if necessary, in pursuit of
steroid-free remission. Ophthalmologists not comfort-
able with prescribing and monitoring immunomo-
dulatory or biologic therapies should not delay in
collaborating with a rheumatologist familiar with the
administration of these drugs, or referring patients to
another specialist, as the long-term consequences of
prolonged corticosteroid therapy are undesirable at best,
not to mention the vision-threatening outcomes of
recurrent inflammation.
Abbreviations
HLA, human leukocyte antigen; IL, interleukin; TNF,
tumor necrosis factor.
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